Oneview Healthcare’s Q2 Cash Down €4M, Customer Receipts Up 51% H1 2025

Financial Overview

Oneview Healthcare PLC disclosed a notable reduction in its cash reserves during the second quarter of 2025, with the balance falling to €8.2 million from €12.2 million at the end of March. The company recorded a net cash outflow of €4.0 million, a rise from €3.2 million in the same quarter last year. This increase was primarily due to marginally higher operating expenses, including one-off restructuring costs of €234,000, reflecting strategic adjustments in response to challenging conditions in the Australian private hospital market.

Additionally, timing differences in R&D tax credit receipts contributed to the cash flow variance. The 2024 R&D tax credit was significantly lower and received earlier in the year compared to 2023, impacting quarterly comparisons. Despite these headwinds, customer receipts improved markedly, rising to €2.1 million in Q2 from €1.6 million a year earlier, underpinning a 51% increase in first-half receipts compared to 2024.

Operational Momentum and Customer Growth

Oneview’s operational progress remains robust, particularly in the United States. The company secured two new customers through its Baxter sales channel – Willis Knighton Health in Louisiana and White Plains Hospital in New York. These wins add significant scale to Oneview’s footprint in the US healthcare market. Furthermore, a three-year contract extension with a major recurring revenue customer is expected to boost annual recurring revenue by over 20%, driven by additional bed deployments and price increases.

Deployment projects advanced steadily across multiple sites, including Inova Health’s 1,900-bed system, University of Iowa’s North Liberty campus, Mercy Hospital Fort Smith, and Rady Children’s Health. These implementations highlight Oneview’s expanding presence and the growing adoption of its digital patient engagement platforms.

Innovation and AI Leadership

Oneview is pushing forward with its AI innovation strategy, recently becoming the first ASX-listed healthcare technology company to achieve ISO42001 certification for its Artificial Intelligence Management System. This certification underscores the company’s commitment to ethical AI governance and positions it as a leader in AI-powered healthcare solutions.

The company is broadening its virtual care capabilities by integrating additional AI-powered platforms such as care.ai and Artisight, complementing existing partnerships with Caregility and Teladoc. New product developments include the MyStay interface and the AI care assistant “Ovie,” designed to enhance patient personalization and support through natural interactions and multi-language capabilities.

Complementing these innovations, Oneview is launching a care experience portal to provide real-time insights into patient engagement and workflow coordination, alongside a KPI trending and benchmarking dashboard to help hospitals measure performance and return on investment.

Outlook and Market Position

Despite ongoing uncertainties in the Australian market and broader healthcare funding changes in the US, Oneview remains confident in its growth trajectory. The company reports a strong sales pipeline with over 180 opportunities in the US alone, many in advanced stages expected to close in the second half of 2025. Management anticipates a seasonally stronger second half and looks forward to releasing its half-year results in August.

Oneview’s strategic focus on AI innovation and expanding US market penetration could well define its competitive edge in the evolving digital health landscape. However, the company must navigate the cash flow pressures and market headwinds carefully to sustain momentum.